Zeripatamig is under clinical development by Light Chain Bioscience and currently in Phase I for Marginal Zone B-cell Lymphoma. According to GlobalData, Phase I drugs for Marginal Zone B-cell Lymphoma have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Zeripatamig’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Zeripatamig overview
Zeripatamig is under development for the treatment of B-cell non-Hodgkin lymphoma (NHL) including marginal zone B-cell lymphoma, diffuse large b-cell lymphoma and mantle cell lymphoma. It is administered through oral route. The drug candidate is a bi-specific monoclonal antibody, which acts by targeting CD47 and CD19. It is developed based on Kappa Lambda Body technology.
It was also under development for the treatment of diffuse large B-cell lymphoma, acute lymphocytic leukemia (ALL), melanoma, Richter's transformation, follicular lymphoma, chronic lymphocytic leukemia (CLL), and unspecified B-cell lymphoma.
Light Chain Bioscience overview
Light Chain Bioscience (Light Chain), formerly NovImmune, is a biopharmaceutical company that focuses on the development of monoclonal and bispecific antibodies. The company’s pipeline products include NI-1701 which targets B cell malignancies; NI-1801 for MSLN-positive solid tumors; NILK-2401, NILK-2301 treats CEA-positive solid tumors; NILK-2501 targets GPC3-positive solid tumors; NI-2801 for solid tumors; NIDB-3001 treats infectious diseases; NIDB-3101 for Alzheimer’s disease and other products. It serves for medical and healthcare industries. The company offers partnership opportunities for the development of human bispecific antibodies in various therapeutic areas. Light Chain is headquartered in Geneva, Switzerland.
For a complete picture of Zeripatamig’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
